Daiichi Sankyo is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees draw upon a rich legacy of innovation and a robust pipeline of promising new medicines.
Our 2025 Vision is to become a “Global Pharma Innovator with Competitive Advantage in Oncology”. Anchored by our DXd antibody drug conjugate (ADC) technology, our powerful research engines include biologics, medicinal chemistry, modality and other research laboratories.
For more information please visit www.daiichi-sankyo.eu

Merit Medical Systems, Inc. is a leading manufacturer and marketer of disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy.
Merit Medial manufacture the SCOUT breast tumor localization solution. SCOUT has been clinically demonstrated to drive value and improve patient outcomes as well as improve radiology workflow and significantly reduce OR delays. Using SCOUT, surgeons can precisely target the affected tissue to pinpoint its location within 1mm, which can mean more successful surgeries, optimized breast conservation strategies, and enhanced outcomes for women.
More information on the SCOUT technology can be viewed HERE
For more information, please visit https://www.merit.com

For more than 45 years, Amoena has been synonymous with innovation, passion and competence in the field of breast care. Our high quality recovery care products, breast forms and breast care apparel give breast-operated women a visually perfect result with the highest wearing comfort.
At Amoena, we know no detail is too small when it comes to helping breast-operated women live confidently. Patents for materials and manufacturing methods are proof of our progress but we’ll never stop endeavouring to meet every need with the highest quality products. Since developing the first breast form, we’ve sold more than 17 million, as well as 30 million pieces of breast care apparel. Today, we are proud to support women throughout their journey – from the moment they are diagnosed, to living life to the fullest once more. We call it The Amoena Solution.
For more information, please visit https://www.amoena.com/au/

Sonic Healthcare is Australia’s largest provider of pathology testing and the third largest in the world, with operations in eight countries.
Sonic Genetics is a specialist genetics service that brings together Sonic Healthcare’s national and international expertise to provide a comprehensive range of high quality, accredited genetic tests to doctors, patients and families across Australia.
For further information, please come to our booth, visit www.sonicgenetics.com.au/tests/prosigna or call us on 1800 010 447.

Mentor
A Global Leader in Aesthetic Medicine.
Founded in 1969, Mentor Worldwide LLC is a leading global manufacturer of high quality breast implants.
Headquartered in Santa Barbara, California. Mentor has manufacturing and research operations in the United States and the Netherlands.
Mentor has over 30 years of experience in the manufacture of breast implants and tissue expanders. Our experience and expertise results in quality products you can rely on.
Mentor and our 1,200 worldwide employees strive to provide high-quality products and services to healthcare professionals and patients.
In January 2009, Mentor was acquired by Johnson & Johnson. Together we aim to enhance and restore self-esteem and quality of life. Simply said, our mission is to Make Life More Beautiful.
For more information visit www.jnjmedicaldevices.com/en-AU/companies/mentor.

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help improve patient outcomes, improve the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to better diagnose disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com.

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics have made Roche the leader in personalised healthcare – aims to boldly transform and personalise healthcare to prevent, diagnose and treat each and every patient more effectively, while creating a more sustainable healthcare ecosystem.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in-vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. www.roche-australia.com

Endomag is a medical technology company devoted to improving the global standard of cancer care. The Sentimag® localization platform works with the Magseed® marker and Magtrace® lymphatic tracer to enable physicians to carry out tumor localizations and breast cancer staging using just one platform. With the Sentimag® platform, physicians can now replace wires and radioactivity with more flexible and precise options to revolutionize their breast cancer care. For more information visit https://www.endomag.com/

Aurora BioScience is a leading medical device distribution company. Our network extends across metropolitan and regional areas throughout Australia, New Zealand and the Pacific Islands.
Our growing product range includes some of the world’s most innovative medical products and solutions in cancer care and other specialty areas.
Some of the products on our stand include Trunode, our single-use wireless Gamma Probe with industry leading sensitivity, the range of Faxitron X-Ray Cabinets and Surgical Specimen systems as well as the original scalp cooling system, the DigniCAP for hair preservation during chemotherapy.
We look forward to seeing you at the conference.
For more information visit www.aurorabioscience.com.au.

AstraZeneca is the ninth largest pharmaceutical company operating in Australia. It is one of the country’s largest manufacturers of medicines and is a key exporter to 20 international markets.
AstraZeneca produces medicines in a range of therapeutic areas including Oncology, Cardiovascular & Metabolic Diseases and Respiratory.
AstraZeneca contributes significantly to clinical trials in Australia with over 55 concurrent trials. AstraZeneca’s innovative medicines are used by millions of patients worldwide. For more information visit www.astrazeneca.com.au

Zeiss
Headquartered in Oberkochen, Germany, Carl Zeiss is represented in more than 30 countries, with around 30 production sites and 50 sales/service sites around the world.
ZEISS is a leader in ophthalmic and surgical microscopes from dental to the latest technology neurosurgical systems. Since 1997, ZEISS has also been a leader in Intraoperative Radiotherapy (IORT) with the introduction of INTRABEAM®. Radical surgical methods in the treatment of breast cancer are being replaced by less-invasive, breast-conserving therapy and this trend is appearing in radiotherapy where oncologists are moving from the largely standardised treatment plan to risk-adapted and targeted individualised therapy. Visit the ZEISS stand at AIBC 2021 to learn about the recently published long-term results from the international TARGIT-A breast cancer study.
For more information visit https://www.zeiss.com.au/corporate/home.html

Surgeons Choice continues to exclusively provide sales, support and service for the Navigator range of Sentinel Node Probe systems in Australia.
We are also showcasing two next generation innovative products:
• ProSense by IceCure: A liquid nitrogen Cryoablation System providing the coldest, fastest most stable Cryoablation Technology in the market, for treatment of benign and some malignant breast tumors.
• Margin Probe by Dilon Technologies: A Margin assessment tool which surgeons can identify positive margins in real-time on the lumpectomy specimen enabling them to take additional tissue during the first surgery.
For more information visit https://www.surgeonschoice.com.au/

PreludeDx is the leading personalized breast cancer diagnostics company dedicated to improving outcomes for patients diagnosed with DCIS (Ductal Carcinoma in Situ). The company provides patients and physicians with evidence-based tools to improve patient outcomes and reduce the cost to the healthcare system by helping to ensure women are not over or under treated. For women diagnosed with DCIS, PreludeDx provides a patented molecular test (DCISionRT®) that predicts a woman’s personal likelihood or risk of developing DCIS recurrence in 10 years and invasive breast cancer in 10 years with or without adjuvant radiation therapy after breast conserving surgery. Visit PreludeDx.com
For more information visit https://preludedx.com/

GRC GRC has traditionally identified improved, new technologies for the Breast cancer market. Magseed, Neoprobe and Hydromark offer clinical benefits to surgeons, resulting in better results for patients and hospitals. As GRC continues to implement technologies through specialists means the change to a better way is both welcomed and embraced.
For more information visit https://grcsurgical.com/

Novartis is the largest Australian medicines company, improving the lives of more than 2.8 million patients across Australia and New Zealand. From generics to gene therapy, we are committed to accelerating patient access to life saving treatments.
We are reimagining medicine by using innovative science and technology to address challenging healthcare issues and our rich pipeline has 200+ projects in development and an industry leading clinical trial footprint in Australia.
Our unbossed, curious and inspired culture unites our 700 employees, it is what unleashes the power of our people and is at the heart of the work we do each day.
For more information visit https://www.novartis.com/

Myriad Genetics is a leading personalised medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercialises molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.
EndoPredict® provides accurate results for patients diagnosed with ER+, HER2-, early-stage breast cancer with either node-negative or node-positive disease (1-3 nodes). The test integrates a 12-gene molecular score with pathology to provide results for early and late recurrence, and accurately predicts an individualised absolute chemotherapy benefit to help make the right treatment decisions for a patient’s breast cancer.
For more information visit www.myriad.com

Sonic Healthcare, provider of the TGA registered Prosigna® Breast Cancer Prognostic Gene Signature Assay, in partnership with Veracyte, and Australian distributor, Bio-Strategy, are proud to support the 2021 Australasian International Breast Congress.
Sonic is one of the world’s largest global healthcare companies and Australia’s largest lab services provider. Sonic have been supporting Australian oncologists in offering the Prosigna prognostic test since its introduction in 2015. Bio-Strategy is an established locally-owned, ISO 9001:2015 accredited distributor, delivering technology to the Scientific Community throughout Australasia, and the exclusive distributor of Veracyte throughout Australia and New Zealand.
Prosigna® is the PAM50-based gene signature providing test results profiling a patient’s risk of distant recurrence and classifying tumours into 1 of 4 intrinsic subtypes to best inform clinical treatment decisions. For more information on Prosigna visit www.prosigna.com or www.sonicgenetics.com.au/prosigna

Current Oncology (ISSN 1718-7729; IF 2.257) is an international, scientific, peer-reviewed, open access journal published bi-monthly online by MDPI (from Volume 28 Issue 1-2021). Established in 1994, the journal represents a multidisciplinary medium for clinical oncologists to report and review progress in the management of this disease. The Canadian Association of Medical Oncologists (CAMO) and the Canadian Association of Psychosocial Oncology (CAPO) are affiliated with the journal and their members receive a discount on the article processing charges.
For more information: https://www.mdpi.com/journal/curroncol

Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. For more than a century, we have stayed true to a core set of values—excellence, integrity, and respect for people—that guide us in all we do: discovering medicines that meet real needs, improving the understanding and management of disease, and giving back to communities through philanthropy and volunteerism. We have also been committed to investing in our employees—through competitive salaries, training and development, health, and the opportunity to give back.
For more information: https://www.lilly.com.au/

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Our belief — and the core of our strategy — is that innovative, highly differentiated medicines that provide large clinical benefits in addressing serious diseases are medicines that will not only help patients, but also will help reduce the social and economic burden of disease.
www.amgen.com.au

Mediplast
WHY Mediplast Australia?
We believe essential care deserves our special attention.
We combine global scale and local expertise to provide you with cost-effective customised essential care solutions.
We use our passion, experience and knowledge of essential care practices to create bespoke product, training and aftercare solutions that allows you to save time, money and, most importantly, lives.
You may know us as products like Bellovac® Wound Drains, value added services like Early Discharge with Exudrain®, through our leadership lobbying government for reimbursement, or via education like that found at https://www.mediplastresourcecentre.com.au . However you know us, you can trust that we are By Your Side in HealthCare.

Regional Health Care Group is proud to exhibit the following technology & support the AIBC.
• Paxman® Scalp Coolers; the Australasian & Global market leader for helping cancer patients avoid Chemotherapy induced hair-loss.
• ImpediMed® Non-invasive fluid monitoring for lymphoedema & cancer survivorship
• iCAD XOFT® Radiotherapy System for intraoperative (IORT) Breast Cancer surgery, Gynae & Skin Cancers
• Nanosonics Trophon2 for high-level disinfection of ultrasound probes used in clinical practice
We are highly regarded across Australia & NZ; providing medical consumables supplies & support; delivering quality products, excellent service and cost-savings.
For further information, please visit our website www.rhcg.com.au or call 1300 659 281

Lifehealthcare is focused on providing access to world-leading medical devices for Australian and New Zealand patients, whilst ensuring long-term economic sustainability for our healthcare system.
LifeHealthcare has a broad portfolio of products in various channels that include Spine, Orthopaedics, Robotics, Plastics & Reconstructive Surgery and Interventional Neuro-Vascular surgery.
Our passion is health
Our purpose is making life better for othersFor more information visit www.lifehealthcare.com.au/

Genetic Technologies (GTG) is a diversified genomics driven Preventative Healthcare Company, providing individualised risk assessment of serious disease.
Our GeneType portfolio incorporates over a decade of R&D, including collaborations with prestigious academic and medical establishments.
With the commercialisation of our GeneType for Breast and Colorectal Cancer tests in 2020, the company continues to lead the way in personalised predictive genetic testing.
GeneType has a strong focus on Integrated Genetics (Germline & Polygenic Risk Score) with a commitment to quality, actionable low cost genetic testing.
Our lab is certified by ISO, CLIA and NATA.
For more information, please visit https://genetype.com/

GenesisCare delivers treatment to people with cancer and heart disease, the two largest disease burdens globally. We’re committed to leading the change in how care is designed and given.
Our purpose is to design care experiences that get the best possible life outcomes. We believe that care should be focused on the individual, not just the condition.
GenesisCare are leveraging the experience and expertise of our network to deliver optimal patient treatment whether in a regional centre or capital city. We are investing in treating patients closer to home using state of the art technology.
For more information visit www.genesiscare.com

For more than a century, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Today, MSD continues to be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases that threaten people and animals around the world.
For more information, please visit www.msd-australia.com.au

Breast Cancer Network Australia (BCNA) is the peak national organisation for Australians affected by breast cancer with more than 120,000 members.
Representing the people behind the statistics, BCNA works to ensure the voices of everyday Australians affected by breast cancer are heard and that they receive the very best support, information, treatment and care appropriate to their individual needs.
For more information visit www.bcna.org.au

OncoRes Medical is developing a novel diagnostic imaging system that has the potential to redefine accuracy in cancer surgery for the 17 million patients who are diagnosed with a solid cancer each year.
OncoRes Medical’s imaging system uniquely combines optical coherence tomography and micro-elastography to provide surgeons with a real-time in-cavity assessment of tissue microarchitecture at a scale and resolution approaching histology.
Initially focussed on breast conserving surgery, OncoRes Medical is committed to partnering with surgeons to eliminate the personal, psychological and economic burdens associated with re-excisions through the highly accurate intraprocedural detection of residual breast cancer.
For more information, please visit https://www.oncoresmedical.com/

Natera has developed Signatera, a personalized ctDNA test for molecular residual disease (MRD) detection and recurrence monitoring in patients previously diagnosed with cancer. Signatera’s tumor-informed assay is optimized to detect low levels of ctDNA, with high accuracy in identifying MRD and recurrence with longer lead times. Signatera has been clinically validated in multiple cancer types including colorectal, non-small cell lung, breast, and bladder cancers. Look deeper at https://www.natera.com/oncology/signatera-advanced-cancer-detection/

Founded in 1818, the HARTMANN GROUP is a leading international medical and healthcare company. Over the years, HARTMANN has cultivated a reputation for offering outstanding medical competence and delivering high quality, innovative and dependable products and services.
PAUL HARTMANN Pty Ltd (HARTMANN) was established in 2003 and is the Australian wholly owned subsidiary of the HARTMANN GROUP. HARTMANN supplies three core product ranges to hospitals, aged care, primary care, pharmacy and community. These core ranges cover continence, skin care and wound management products.
For more information, please visit www.hartmann.info/